ASSESSMENT OF P53 EXPRESSION IN NASOPHARYNGEAL CARCINOMA

被引:73
作者
SHEU, LF
CHEN, A
TSENG, HH
LEU, FJ
LIN, JK
HO, KC
MENG, CL
机构
[1] NATL DEF MED CTR,GRAD INST MED SCI,TAIPEI 10750,TAIWAN
[2] NATL DEF MED CTR,TRISERV GEN HOSP,DEPT OTOLARYNGOL,TAIPEI 10750,TAIWAN
[3] NATL DEF MED CTR,TRISERV GEN HOSP,DEPT DENT,TAIPEI 10750,TAIWAN
[4] VET GEN HOSP KAOSIUNG,DEPT PATHOL,KAOHSIUNG,TAIWAN
[5] NATL TAIWAN UNIV,DEPT BOT,TAIPEI 10764,TAIWAN
关键词
P53; PROTEIN; IMMUNOHISTOCHEMISTRY; NASOPHARYNGEAL CARCINOMA;
D O I
10.1016/0046-8177(95)90137-X
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We analyzed the expression of the p53 protein by immunohistochemical methods from 101 patients with nasopharyngeal carcinoma (NPC): 24 with NPC and dysplastic lesions adjacent to carcinoma and 14 with primary and metastatic specimens. Ninety-six of 101 lesions (95%) had detectable p53 protein in the nuclei of tumor cells, indicating that overexpression of the p53 protein might be closely associated with NPC. Among 24 patients who had NPC and dysplastic lesions adjacent to carcinoma, 19 of the dysplastic lesions (79.2%) and 22 of the carcinomas (91.7%) showed positive staining for the p53 protein. In dysplastic epithelia p53 antigenicity was generally in a basal location. The significant association of p53 expression in NPC and dysplastic lesions adjacent to carcinoma (P < .0001, Fisher's exact probability test) suggests that p53 overexpression seems to occur at an early stage in the development of NPC. p53 expression in NPC does not correlate with histological grading, degree of lymphocytic infiltration between tumor cells, clinical stage, sex, or age (P > .05, chi-squared test). A comparison of p53 expression between primary and metastatic NPC was performed in 14 lesions. Although the p53 protein was consistently expressed in primary and metastatic tumor cells, there was no significant difference in p53 expression in both distinct but related lesions (P > .05, paired t-test). Our results suggest that the association of overexpression of the p53 protein in NPC may not be indicative of a mutant type p53 protein. HUM PATHOL 26:380-386. Copyright (C) 1995 by W.B. Saunders Company
引用
收藏
页码:380 / 386
页数:7
相关论文
共 38 条
[1]  
ABLASHI DV, 1983, CANCER RES, V43, P2375
[2]   TUMOR SUPPRESSOR GENE-PRODUCTS, PROLIFERATION, AND DIFFERENTIATION MARKERS IN LUNG NEUROENDOCRINE NEOPLASMS [J].
BARBARESCHI, M ;
GIRLANDO, S ;
MAURI, FA ;
ARRIGONI, G ;
LAURINO, L ;
DALLAPALMA, P ;
DOGLIONI, C .
JOURNAL OF PATHOLOGY, 1992, 166 (04) :343-350
[3]  
BARTEK J, 1991, ONCOGENE, V6, P1699
[4]   MOLECULAR THEMES IN ONCOGENESIS [J].
BISHOP, JM .
CELL, 1991, 64 (02) :235-248
[5]  
CHANG YS, 1989, CANCER RES, V49, P6752
[6]   DEGRADATION OF NUCLEAR ONCOPROTEINS BY THE UBIQUITIN SYSTEM INVITRO [J].
CIECHANOVER, A ;
DIGIUSEPPE, JA ;
BERCOVICH, B ;
ORIAN, A ;
RICHTER, JD ;
SCHWARTZ, AL ;
BRODEUR, GM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (01) :139-143
[7]  
DAVIDOFF AM, 1991, SURGERY, V110, P259
[8]  
DETHE G, 1986, EPSTEINBARR VIRUS RE, P236
[9]  
DOMAGALA W, 1993, AM J PATHOL, V142, P669
[10]   ALTERATIONS OF THE P53 GENE IN NASOPHARYNGEAL CARCINOMA [J].
EFFERT, P ;
MCCOY, R ;
ABDELHAMID, M ;
FLYNN, K ;
ZHANG, Q ;
BUSSON, P ;
TURSZ, T ;
LIU, E ;
RAABTRAUB, N .
JOURNAL OF VIROLOGY, 1992, 66 (06) :3768-3775